Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.

Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. The company went public …

TEMPUS® is a technology company that has built the world's largest library of clinical and molecular data and an operating system to make that information accessible and useful for …

5 days ago · Tempus AI ’s ( TEM Quick Quote TEM - Free Report) third-quarter 2025 results highlight the growing strategic importance of its Insights and Data & Services business, which …

Jan 23, 2025 · In 2015, with a vision to revolutionize how doctors use data in clinical settings, Lefkofsky established Tempus. The initial aim was to create a system where doctors could …

2 days ago · A well-known analyst believes this AI healthcare stock has room to soar. According to data provided by S&P Global Market Intelligence, Tempus AI stock rose 10.9% from the end …

2 days ago · Tempus is a public company based in Chicago (United States), founded in 2015 by Eric Lefkofsky. It operates as an AI-based precision medicine solutions for oncology.

We’re looking for people who can change the world. Who question the status quo and don’t shy away from tough problems. For the builders who are never done building and the learners who …

Launched in the United States in 2015, Tempus is now one of the largest sequencers of cancer patients in the world. Having built its platform for oncology, it has expanded to …

1 day ago · Tempus AI (TEM) is drawing new attention after analysts highlighted strong momentum from its Ambry acquisition, advances in rare disease testing, and a new …